BIO.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:36):

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments...

Stats
Dagens volum	100.00
Gjennomsnittsvolum	154.00
Markedsverdi	1.40B
EPS	€0 ( 2024-03-28 )
Neste inntjeningsdato	( €0 ) 2024-05-06
Last Dividend	€0.0400 ( 2019-05-08 )
Next Dividend	€0 ( N/A )
P/E	13.00
ATR14	€0 (0.00%)

Biotest AG Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Biotest AG Økonomi

Annual	2023
Omsetning:	€684.60M
Bruttogevinst:	€271.90M (39.72 %)
EPS:	€3.21

FY	2023
Omsetning:	€684.60M
Bruttogevinst:	€271.90M (39.72 %)
EPS:	€3.21

FY	2022
Omsetning:	€516.10M
Bruttogevinst:	€124.90M (24.20 %)
EPS:	€-0.800

FY	2021
Omsetning:	€515.60M
Bruttogevinst:	€80.70M (15.65 %)
EPS:	€-1.610

Financial Reports:

No articles found.

Biotest AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Biotest AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.59 - good (75.92%) | Divividend Growth Potential Score: 1.201 - No dividend growth expected in the near future

Information

First Dividend	€0.0667	2000-07-17
Last Dividend	€0.0400	2019-05-08
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	€1.683	--
Avg. Dividend % Per Year	0.00%	--
Score	2	--
Div. Sustainability Score	7.59
Div.Growth Potential Score	1.201
Div. Directional Score	4.40	--

Next Divdend (Est)
(2024-12-30)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.00

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
INN1.DE	Ex Dividend Junior	2023-08-07	Semi-Annually	0.00%
SWF.DE	Ex Dividend Junior	2023-09-01	Quarterly	0.00%
CVS.DE	Ex Dividend Knight	2023-10-19	Quarterly	0.00%
LUS1.DE	Ex Dividend Junior	2023-06-23	Annually	0.00%
2M6.DE	Ex Dividend Knight	2023-09-21	Quarterly	0.00%
VFP.DE	Ex Dividend Junior	2023-09-08	Quarterly	0.00%
ENI.F	Ex Dividend Knight	2023-11-20	Semi-Annually	0.00%
NVJP.DE	Ex Dividend Knight	2023-08-18	Annually	0.00%
AHC.DE	Ex Dividend Knight	2023-09-15	Quarterly	0.00%
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.217	1.500	5.65	8.48	[0 - 0.5]
returnOnAssetsTTM	0.107	1.200	6.43	7.71	[0 - 0.3]
returnOnEquityTTM	0.368	1.500	7.02	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.963	0.800	5.18	4.15	[1 - 3]
quickRatioTTM	0.845	0.800	9.74	7.79	[0.8 - 2.5]
cashRatioTTM	0.308	1.500	9.40	10.00	[0.2 - 2]
debtRatioTTM	0.441	-1.500	2.64	-3.97	[0 - 0.6]
interestCoverageTTM	4.47	1.000	9.46	9.46	[3 - 30]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
freeCashFlowPerShareTTM	-0.884	2.00	-0.442	-0.884	[0 - 20]
debtEquityRatioTTM	1.278	-1.500	4.89	-7.33	[0 - 2.5]
grossProfitMarginTTM	0.432	1.000	6.13	6.13	[0.2 - 0.8]
operatingProfitMarginTTM	0.251	1.000	6.98	6.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.00251	1.000	-1.125	-1.125	[0.2 - 2]
assetTurnoverTTM	0.493	0.800	-0.0455	-0.0364	[0.5 - 2]
Total Score				7.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.63	1.000	9.03	0	[1 - 100]
returnOnEquityTTM	0.368	2.50	8.09	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.884	2.00	-0.295	-0.884	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.115	1.500	-2.57	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00225	1.000	-2.56	0	[0.1 - 0.5]
Total Score				1.201

Biotest AG

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.